2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
September 24, 2019 07:30 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
September 17, 2019 07:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Present at Upcoming Conferences
September 06, 2019 07:30 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Steadman Philippon Research Institute Awarded First NIH Award Vail, Colorado, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI) has received a research award from the National Institutes of Health (NIH) to investigate bone...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 06, 2019 16:00 ET | Capricor Therapeutics, Inc.
Positive Results from HOPE-2 Interim Analysis Reported in July To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6
July 30, 2019 08:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, July 30, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
July 25, 2019 07:00 ET | Capricor Therapeutics, Inc.
--Independent Data Safety Monitoring Board recommends to continue HOPE-2 study-- --Capricor to resume treating currently enrolled patients-- LOS ANGELES, July 25, 2019 (GLOBE NEWSWIRE) -- Capricor...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy
July 17, 2019 07:00 ET | Capricor Therapeutics, Inc.
-- Conference Call Today at 1 PM ET/10 AM PT --                                                   LOS ANGELES, July 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) announced...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy
July 15, 2019 06:00 ET | Capricor Therapeutics, Inc.
--Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb, Grip Strength and Inspiratory Flow Reserve in the Randomized Double-Blind Placebo Controlled...
Going the Distance for Duchenne
July 09, 2019 15:34 ET | Jett Foundation
Plymouth, MA, July 09, 2019 (GLOBE NEWSWIRE) -- A group of inspiring young people will join Jett Foundation, a non-profit organization dedicated to awareness and helping fight Duchenne muscular...